⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27168862 | 0.97 | — | — | |
| SCHEMBL379211 | 0.82 | — | — | |
| SCHEMBL3051327 | 0.80 | — | — | |
| SCHEMBL4047411 | 0.79 | CYP2D6 (0.45) | — | |
| SCHEMBL17634017 | 0.78 | MAPK1 (0.44) | — | |
| SCHEMBL17275134 | 0.78 | MAPK1 (0.44) | — | |
| SCHEMBL4155026 | 0.78 | MAPK1 (0.44) | — | |
| SCHEMBL20919713 | 0.78 | MAPK1 (0.44) | — | |
| SCHEMBL3050112 | 0.78 | MAPK1 (0.44) | — | |
| SCHEMBL4230147 | 0.78 | MAPK1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024071594-A1 | COMPOSITION COMPRISING QUINAZOLINE SALT COMPOUND FOR TREATMENT OF ARTHRITIS AND PREPARATION METHOD THEREFOR | 주식회사 베노바이오 | 2024-04-04 | — | — | WO | claimed |
| EP-4334326-A1 | CHEMICALLY LINKABLE NUCLEAR TARGETING TAGS | Sigma-Aldrich Co. LLC (US) | 2024-03-13 | — | — | EP | claimed |
| CN-115677551-A | Preparation process of 2-oxopyrrolidine-3-ethyl formate | 武汉市振邦生物科技有限公司 | 2023-02-03 | — | — | CN | claimed |
| EP-4660185-A1 | NAV1.7- AND/OR NAV1.8-INHIBITING AMIDES, PROCESSES FOR THE PREPARATION THEREOF, COMPOSITIONS, USES, METHODS FOR TREATMENT USING SAME, AND KITS | Eurofarma Laboratórios S.A. (BR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250296912-A1 | AFFINITY ILLUDOFULVENE CONJUGATES | Illudent, Inc. (US) | 2025-09-25 | — | — | US | disclosed |
| EP-4587012-A1 | COMBINATION OF MACROCYCLIC CFTR MODULATORS WITH CFTR CORRECTORS AND / OR CFTR POTENTIATORS | Idorsia Pharmaceuticals Ltd (CH) | 2025-07-23 | — | — | EP | disclosed |
| EP-4583976-A1 | HETEROCYCLIC DERIVATIVES AS JANUS KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2025-07-16 | — | — | EP | disclosed |
| EP-4562012-A1 | SUBSTITUTED IMIDAZOPYRAZINE COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK3 | CELGENE CORPORATION (US) | 2025-06-04 | — | — | EP | disclosed |
| WO-2025083472-A2 | PROTAC COMPOUNDS BINDING KEAP1 UBIQUITIN LIGASE FOR TARGETED PROTEIN DEGRADATION | SEED THERAPEUTICS US, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-12269793-B2 | Affinity illudofulvene conjugates | AF CHEMICALS, LLC (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4506348-A1 | ISOXAZOLE-HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | Shanghai Simrd Biotechnology Co., Ltd (CN) | 2025-02-12 | — | — | EP | disclosed |
| EP-0971904-A1 | NOVEL 1-AMINO-3 BENZYL URACILS | BASF AKTIENGESELLSCHAFT (DE) | 2000-01-19 | — | — | EP | disclosed |
| WO-1998042682-A1 | NOVEL 1-AMINO-3 BENZYL URACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-10-01 | — | — | WO | disclosed |
| CN-1189824-A | 1-amino-3-benzyluracils | BASF AG (DE) | 1998-08-05 | — | — | CN | disclosed |
| EP-0835248-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1997001543-A1 | 1-AMINO-3-BENZYLURACILS | BASF AKTIENGESELLSCHAFT (DE) | 1997-01-16 | — | — | WO | disclosed |
| EP-0746326-A1 | OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-11 | — | — | EP | disclosed |
| WO-1995018623-A1 | OLIGOMERIC COMPOUNDS HAVING NITROGEN-CONTAINING LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| EP-0401707-A1 | Heterocyclic triazin or triazolo compounds having serotonin 2-receptor antagonistic activity | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1990-12-12 | — | — | EP | disclosed |
| US-4031226-A | ANTIEMETIC, PSYCHOTROPIC | JANSSEN PHARMACEUTICA N.V. (BE) | 1977-06-21 | — | — | US | disclosed |